<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448825</url>
  </required_header>
  <id_info>
    <org_study_id>11620</org_study_id>
    <secondary_id>R01DA019804</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00448825</nct_id>
  </id_info>
  <brief_title>Novel Pharmacotherapy for Dual Dependence</brief_title>
  <official_title>Novel Pharmacotherapy for Dual Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bankole Johnson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Topiramate and Cognitive Behavioral
      Therapy for the treatment of alcohol and cocaine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our objective is to understand the basic mechanisms that underpin substance dependence, and
      to develop efficacious treatments for individuals with comorbid cocaine and alcohol
      dependence.

      Participants in this study will be randomly assigned to receive either 300 mg per day of
      topiramate or placebo. In addition, participants will receive weekly cognitive behavioral
      therapy for 12 weeks.Follow-up visits will occur at 2 weeks and 1,2,, and 3 months following
      completion of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The topiramate group will be superior to the placebo group on the following outcome measures:increasing the weekly mean proportion of cocaine-free days, decreasing self-reported drinking, and decreasing craving for cocaine and alcohol.</measure>
    <time_frame>According to Preston Rules from weeks 6 to 12.</time_frame>
    <description>Alcohol - assessed by self-report of use (TLFB,DD,DDD,PDA, PHDD), biochemical markers (GGT, CDT), OCDS
Cocaine - assessed by self-report of use (CTFB, substance use inventory, QFI),urine assay for benzoylecgonine, and CCQ-NOW</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>a. Cocaine free weeks; b. Topiramate, compared with placebo, will be associated with an improvement in psychosocial functioning as exemplified by improved general well-being, social functioning, and quality of life.</measure>
    <time_frame>According to Preston Rules from weeks 1 to 12</time_frame>
    <description>Cocaine free weeks is assessed by a combination of self-report of use and urine assays;
Assessed by increased scores in the following assessments: CGI, BSI, Q-LES-Q, DrInC, SFQ, medication compliance, CIWA-Ar, POMS, BIS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Cognitive Behavioral Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate + Cognitive Behavioral Therapy</intervention_name>
    <description>Topiramate up to 300 mg per day</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Cognitive Behavioral Therapy</intervention_name>
    <description>Placebo twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be men and women between the ages of 18 years and older.

          -  Must meet at least three of the seven DSM IV diagnostic criteria for alcohol and
             cocaine dependence.

          -  Express a desire for treatment.

          -  Literacy in English and ability to read, understand, and complete the ratings scales
             and questionnaires accurately, follow instructions, and make use of the behavioral
             treatments are required.

          -  Prospective subjects must report cocaine use of at least once per month and alcohol
             consumption of ≥21 drinks/week and ≥14 drinks/week for men and women respectively,
             during the past 30 days

          -  At least one positive urine drug screen for cocaine at screen or baseline prior to
             randomization.

        Exclusion Criteria:

        Please contact site for additional information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bankole Johnson, DSc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mindy Borszich</last_name>
    <phone>1-888-882-2345</phone>
    <email>mcb3x@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Jenkins-Mendoza</last_name>
    <phone>(434)243-0562</phone>
    <email>emj9c@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Center for Addiction Research and Education</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Borszich</last_name>
      <phone>888-882-2345</phone>
      <email>mcb3x@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Jenkins-Mendoza</last_name>
      <phone>(434)243-0562</phone>
      <email>emj9c@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bankole Johnson, DSc,MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nassima Ait-Daoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Addiction Research and Education</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Borszich</last_name>
      <phone>888-882-2345</phone>
      <email>mcb3x@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Jenkins-Mendoza</last_name>
      <phone>(434)243-0562</phone>
      <email>emj9c@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bankole Johnson, DSc,MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nassima Ait-Daoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medicine.virginia.edu/clinical/departments/psychiatry/sections/neurobiologicalstudies/uvacare</url>
    <description>(UVA CARE website)</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Bankole Johnson</investigator_full_name>
    <investigator_title>Chair of Psychiatry and Neurobehavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>alcohol dependence</keyword>
  <keyword>alcoholism</keyword>
  <keyword>cocaine addiction</keyword>
  <keyword>cocaine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

